Are there really risks with topical finasteride?

Topical finasteride is applied to the scalp instead of swallowed, with the aim of reaching the follicles while keeping blood levels low. It is a prescription medicine, and it is still finasteride. This article sets out what the published reports describe: the reactions specific to putting the drug on the skin, the rare systemic effects, the case-report evidence, and — for comparison — the better-documented side effects of the oral form.

Local skin reactions

The side effects unique to topical application are localized skin reactions. Because the solutions contain vehicles like alcohol, propylene glycol, or other solvents (similar to topical minoxidil solutions), they can irritate the skin. Documented local side effects include scalp itching (pruritus), redness, burning sensation, or contact dermatitis at the application site. These effects are usually mild to moderate and limited to the scalp. For instance, a patient might experience some dandruff or dry scalp from the topical formulation. Reviews of topical finasteride describe scalp irritation and dermatitis in a minority of users. Clinicians commonly respond by reducing the application frequency or changing the formulation base, since compounded versions use different vehicles; treating the dermatitis itself is a prescribing decision, so raise it with your prescriber rather than reaching for a medicated shampoo on your own. Allergic contact dermatitis to finasteride itself is very rare; most often it’s sensitivity to the vehicle.

Rare or Theoretical Risks:

Blood levels are lower with topical finasteride, but some of the drug still reaches the bloodstream. The US FDA states that there is no FDA-approved topical finasteride, and in 2025 it warned about compounded topical products after receiving 32 reports (2019–2024) of effects including erectile dysfunction, low libido, depression, anxiety, suicidal thoughts, "brain fog", fatigue, insomnia and testicular pain; the FDA says most of these reports described effects that continued after the product was stopped (FDA, 2025). Reports like these cannot show how often such effects happen or prove the product caused them. Another consideration is that if a woman who is pregnant comes into contact with topical finasteride (e.g. via physical contact with treated scalp or hands), there is a risk to a male fetus (finasteride can cause abnormalities in male genital development).

Precautions are therefore needed to avoid exposing a pregnant partner, and they are the same in principle as the warnings about women handling crushed finasteride tablets.

The trial data on topical finasteride report much lower blood levels and a smaller reduction in serum DHT than the oral drug, and clinicians commonly describe the systemic side-effect profile as more favourable on that basis. That is a reasonable inference, but it is an inference: no study has been powered to measure whether sexual side effects are genuinely rarer on the topical form. Some men who stopped oral finasteride because of sexual side effects report tolerating the topical version, and some report the same problems on it. Topical finasteride is not risk-free. If you develop sexual, mood or other unexpected symptoms on it, treat that the same way you would on the oral drug: report it to your prescriber.

The most-cited such report is Irwig and Kolukula's 2011 interview study of 71 otherwise healthy men, aged 21 to 46, who reported new sexual side effects while taking finasteride for hair loss and whose symptoms persisted at least three months after they stopped. Among those men, 94% reported low libido and 92% reported erectile dysfunction, with decreased arousal in 92% and problems with orgasm in 69%. Note what that design does and does not show: the men were recruited because they had persisting symptoms, so the percentages describe that group, not the risk to an average user. The study was uncontrolled and has been met with scepticism, but it drew attention to possible lasting effects in some men; it cannot show how many men are affected or that finasteride caused the symptoms. Case reports in the same area describe severe depression and suicidal ideation attributed by the reporters to finasteride use. The MHRA's 2024 drug safety update reminds prescribers and patients of the risk of psychiatric side effects and of sexual side effects that may persist after treatment is stopped. Its May 2026 update states that finasteride is associated with depression, suicidal thoughts and sexual dysfunction which may persist after treatment is stopped (MHRA, 2026). In 2025 the European Medicines Agency confirmed suicidal thoughts as a side effect of finasteride tablets, with a frequency that cannot be estimated, and found no evidence linking suicidal thoughts to the finasteride skin spray (EMA, 2025). That is an absence of evidence for the spray, not proof that it is free of this risk. Causality in individual cases is hard to establish, and the frequency of persistent effects is not known.

Allergic reactions

Systemic allergic reactions to finasteride are uncommon. Jia and Ran (2023) reported one 76-year-old man taking oral finasteride for an enlarged prostate who developed a widespread maculopapular rash after two months. It cleared after he stopped the drug and was treated with an antihistamine and a topical steroid. It is a single case, and it did not involve the topical form.

Topical finasteride: case observations

Published case reports specific to topical finasteride are sparse. In the phase III trial of a 0.25% topical spray, treatment-related sexual side effects were reported in 2.8% of men on the spray, 3.3% on placebo and 4.8% on oral finasteride over 24 weeks; the trial was not designed to show a difference between these groups (Piraccini et al., 2022). Longer-term data on the topical form are limited. Community members do post accounts of significant side effects on topical finasteride, and those accounts are not published data. What the case-report literature shows is that rare adverse outcomes can occur, and that anyone using it should watch for unexpected symptoms — breast changes, mood, anxiety or cognitive changes, semen changes, testicular pain, or allergic reactions — and report them. The level of evidence is low: these reports enumerate possibilities, they do not quantify risk.

(Quality note: Case reports are uncontrolled observations and cannot prove causation. They often involve unusual circumstances or extreme reactions, so they should not be read as representative of the average user's experience. They are included here because they are the only published evidence specific to the topical form.)

The oral form is far better documented, and it is the natural comparison.

Oral finasteride side effects

Finasteride’s best-known side effects are sexual dysfunction symptoms, due to its systemic DHT reduction. In the one-year clinical trials used for US approval, 36 of 945 men (3.8%) taking finasteride 1 mg reported at least one drug-related sexual side effect, compared with 20 of 934 (2.1%) taking placebo (Propecia prescribing information). Some independent studies report higher rates in real-world use, and the figures vary between studies depending on how side effects were asked about. In the pivotal trials, sexual side effects resolved in men who stopped (Propecia prescribing information). The label also lists post-marketing reports of sexual dysfunction that continued after stopping, and how often this happens is unknown. Symptoms that persist after stopping are sometimes called “post-finasteride syndrome” (PFS), a contested term. Case series of PFS have documented men with prolonged sexual dysfunction, where symptoms like low libido and ED lasted for months or years after stopping finasteride. While the existence and frequency of PFS are debated, regulatory agencies have added warnings about potential persistent sexual side effects.

The oral drug's documented side effects are not only sexual. The same label lists breast tenderness (0.4% vs 0.1% on placebo) and breast enlargement (0.5% vs 0.1%) in the trials, a small fall in ejaculate volume (about 11% vs 8% at 48 weeks), and post-marketing reports of male infertility or poor semen quality (normalisation or improvement after stopping has been reported), testicular pain, breast tenderness or enlargement, male breast cancer (the label says the relationship to long-term use is unknown) and hypersensitivity reactions including angioedema (Propecia prescribing information). The trial figures carry a limit: the approval trials recorded sexual and physical side effects during treatment for a year or less and did not measure mood or cognition, so they cannot answer questions about those or about what happens after stopping. A review of 34 finasteride hair-loss trials found that none reported safety adequately and that most followed men for a year or less (Belknap et al., 2015).

Psychological side effects

Psychological effects have also been associated with oral finasteride. Some users report mood swings, depression, or anxiety. In April 2024 the UK's MHRA issued a drug safety update reminding prescribers and patients that finasteride has been associated with depressed mood, depression, and suicidal thoughts, and asked men taking it to stay vigilant for psychiatric and sexual side effects; the update does not establish a causal link. Controlled studies have not consistently shown an increase in depression with finasteride, while surveys and individual reports suggest it may affect mood in susceptible people. The approval trials did not measure mood at all. The controlled evidence that exists comes mostly from older men taking 5-alpha-reductase inhibitors for the prostate: a Canadian cohort of 93,197 men aged 66 and over found higher rates of new depression (hazard ratio 1.94 in the first 18 months, then 1.22) and self-harm (1.88 in the first 18 months) but no increase in suicide; the absolute increases were small, about 17 self-harm and 237 depression events per 100,000 person-years (Welk et al., 2017). In younger hair-loss users the evidence is weaker: among 61 former users with persistent sexual symptoms, 75% had depressive symptoms and 44% reported suicidal thoughts, against 10% and 3% of 29 never-users, but these men were recruited because they were symptomatic, so the figures are not a rate (Irwig, 2012). In the WHO adverse-event database, reports of suicidality and psychological effects were disproportionately high for finasteride in men under 45 and in hair-loss use, and absent in older prostate patients; reports rose after the 2012 label change, and the authors note that publicity can drive reporting (Nguyen et al., 2021). Anxiety and cognitive complaints ("brain fog") are also reported. In one small study, symptomatic former users reported more cognitive complaints than current users and never-users but scored normally on objective cognitive testing, and showed no androgen deficiency (Basaria et al., 2016). Whether these symptoms are caused by finasteride, and whether they are permanent, is not settled. The UK regulator (MHRA, May 2026) advises stopping finasteride 1 mg immediately and contacting a doctor if depression or suicidal thoughts develop. If you have thoughts of harming yourself, seek emergency help right away. Other reported side effects include headache and, rarely, allergic reactions such as a rash (see Allergic reactions above).

Before you use it

Topical and oral finasteride are both prescription-only medicines, and topical finasteride is in many places a compounded product whose strength and vehicle vary by pharmacy. Talk to a doctor or pharmacist before starting or combining finasteride in either form. The UK regulator (MHRA, May 2026) advises stopping finasteride 1 mg immediately and contacting a doctor if depression or suicidal thoughts develop; its update does not mention the topical form, so if depression or suicidal thoughts develop on topical finasteride, contact a doctor promptly too. If you have thoughts of harming yourself, seek emergency help right away. If you develop sexual, mood or cognitive symptoms, or a rash, contact your prescriber rather than waiting to see whether it passes.

Finasteride is contraindicated in pregnancy: it can cause abnormal development of the external genitals in a male fetus. A woman who is or may become pregnant must not take finasteride and must not come into contact with the topical solution or with crushed or broken tablets. Let the scalp dry fully and wash your hands after applying the topical form.

Sources

Jia, H., & Ran, L. (2023). Maculopapular drug eruption caused by finasteride: A case report. Clinical, Cosmetic and Investigational Dermatology, 16, 3359–3361. https://doi.org/10.2147/CCID.S426747

Irwig, M. S., & Kolukula, S. (2011). Persistent sexual side effects of finasteride for male pattern hair loss. The Journal of Sexual Medicine, 8(6), 1747–1753. https://doi.org/10.1111/j.1743-6109.2011.02255.x (PubMed 21418145)

Medicines and Healthcare products Regulatory Agency. (2024, April 29). Finasteride: Reminder of the risk psychiatric side effects and of sexual side effects (which may persist after discontinuation of treatment). GOV.UK. https://www.gov.uk/drug-safety-update/finasteride-reminder-of-the-risk-psychiatric-side-effects-and-of-sexual-side-effects-which-may-persist-after-discontinuation-of-treatment

Medicines and Healthcare products Regulatory Agency. (2024, April 29). Men on finasteride asked to stay vigilant for possible psychiatric and sexual side effects. GOV.UK. https://www.gov.uk/government/news/men-on-finasteride-asked-to-stay-vigilant-for-possible-psychiatric-and-sexual-side-effects

Medicines and Healthcare products Regulatory Agency. (2026, May 11). Finasteride and dutasteride: updated safety warnings for psychiatric side effects and sexual dysfunction. GOV.UK. https://www.gov.uk/drug-safety-update/finasteride-and-dutasteride-updated-safety-warnings-for-psychiatric-side-effects-and-sexual-dysfunction

European Medicines Agency. (2025). Finasteride- and dutasteride-containing medicinal products: Article 31 referral. https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products

U.S. Food and Drug Administration. (2025, April 22). FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-consumers-potential-risks-associated-compounded

Piraccini, B. M., Blume-Peytavi, U., Scarci, F., et al. (2022). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology, 36(2), 286–294. https://doi.org/10.1111/jdv.17738 (PubMed 34634163)

Organon. Propecia (finasteride) tablets, prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f904709-65aa-44ce-b144-b4c8a0416e36

Belknap, S. M., Aslam, I., Kiguradze, T., et al. (2015). Adverse event reporting in clinical trials of finasteride for androgenic alopecia: A meta-analysis. JAMA Dermatology, 151(6), 600–606. https://pubmed.ncbi.nlm.nih.gov/25830296/

Welk, B., McArthur, E., Ordon, M., Anderson, K. K., Hayward, J., & Dixon, S. (2017). Association of suicidality and depression with 5α-reductase inhibitors. JAMA Internal Medicine, 177(5), 683–691. https://pubmed.ncbi.nlm.nih.gov/28319231/

Irwig, M. S. (2012). Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. The Journal of Clinical Psychiatry, 73(9), 1220–1223. https://pubmed.ncbi.nlm.nih.gov/22939118/

Nguyen, D. D., Marchese, M., Cone, E. B., et al. (2021). Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatology, 157(1), 35–42. https://pubmed.ncbi.nlm.nih.gov/33175100/

Basaria, S., Jasuja, R., Huang, G., et al. (2016). Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss. The Journal of Clinical Endocrinology & Metabolism, 101(12), 4669–4680. https://pubmed.ncbi.nlm.nih.gov/27662439/

Mysore, V. (2012). Finasteride and sexual side effects. Indian Dermatology Online Journal, 3(1), 62–65. https://doi.org/10.4103/2229-5178.93496

Estill, M. C., Ford, A., Omeira, R., & Rodman, M. (2023). Finasteride and dutasteride for the treatment of male androgenetic alopecia: A review of efficacy and reproductive adverse effects. Georgetown Medical Review, 7(1). https://doi.org/10.52504/001c.88531